Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

DOI: 10.1080/2162402X.2018.1424674

Keywords: Ipilimumab, checkpoint inhibitors, immunogenicity, anti-drug antibodies, cancer, malignant melanoma

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text